Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix AI LSE:RENX London Ordinary Share GB00BYWL4Y04
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +5.00p +3.64% 142.50p 135.00p 150.00p 148.50p 139.00p 139.00p 69,856 13:37:52
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology - - - - 76.69

Renalytix AI Share Discussion Threads

Showing 26 to 49 of 50 messages
Chat Pages: 2  1
The inaugural interim results makes for interesting reading and details the excellent progress to date. They also detail the near/medium term operational milestones, which they appear confident about delivering upon and is very encouraging, especially as they envisage that they represent value inflection points. Publication, in the coming days, of the results from a confirmation study will no doubt also make for encouraging reading.
Another encouraging update, with another impressive list of experts assembled, which sends a message regarding the need/opportunity and indeed the Renalytix technology offering/potential.
'Beyond' what we already know, it will be interesting to learn what the Investor Briefing will be communicating, but one would assume there may be more to tell.
An interesting read that puts some perspective on the level of interest and the rate of adoption in AI - Partners Explores “Transformative” Realities of AI in Healthcare At the World Medical Innovation Forum, Partners HealthCare will combine futurism with reality to explore the state of artificial intelligence in healthcare. The three-day event usually focuses on a different theme every year. Past conferences have zeroed in on neurology, oncology, and cardiac care, exploring the intersection between diagnostics, best practices, analytics, and the financial strategies that make it all work. In 2018, Partners shifted its gaze to artificial intelligence in healthcare, with the goal of breaking down the challenges and opportunities of machine learning to provide enhanced decision support to clinicians across the care continuum. Normally, the 2019 edition of the WMIF would follow the pattern and move on to yet another area of focus. But leaders at the health system made an atypical decision: to stick with artificial intelligence for another year so attendees could move even deeper into this complex, fascinating area of study. “Typically, our Disruptive Dozen showcase looks at what’s coming in the next decade,” he said. “This year, we’re looking at what’s going to overhaul healthcare in the next 12 months. That’s how quickly AI is moving.” Full article - hTTps://
Worth a look, AKESOGEN - Expert in the field of Genomics, AKESOgen provides premier research services and the highest quality data for scientists doing clinical or basic research across the world. Serving clients in biotech, pharmaceutical, academic and government research/testing, the company delivers data at the apex of quality, enhances clients’ productivity and enables them to meet important deadlines by offering the best in customer service and a collaborative, consultative relationship. Expertise, Advice, Consultation, Responsiveness and Unsurpassed Data Quality: AKESOgen is Your Research Partner. hTTp://
Edited a few typo's!
A very encouraging development announced today, with an expansion and ratcheting up in both capacity and capabilities, capabilities which are beyond the initial focus on kidney disease. In my book, Renalytix has just put a foot into a much larger space within the healthcare artificial intelligence market, especially in support of pharmaceutical companies looking to leverage off of the advantages of deploying AI. Furthermore, the ability to develop companion diagnostics, which in turn also helps to support pharma's drug authorisation and indeed which becomes an integral part, such that it is essential for the safe and effective use of a corresponding therapeutic product, obviously has great potential. This sets Renalytix apart from even the likes Google's Deep Mind, and not in an insignificant way!
Another positive update indicates that we are firmly on schedule as per IPO and EKF's Investor Presentation.
Today's news is very encouraging in terms of the expanded study and the involvement of other parties, the scale and clinical breadth of which is indeed impressive. It's also encouraging that the time table for commercial launch of the laboratory developed test appears to be on schedule. Given that others are involved in this study, it implies that there is a lot of interest, which appears to bode well for Renalytix stated intention to enter into further collaborations beginning in 2019.
FDA accommodating to realise the reality that AI will indeed change healthcare - January 08, 2019 By Jennifer Bresnick FDA Tackles Artificial Intelligence with New Software Review Plan The FDA is speeding up its regulatory processes to accommodate the new realities of the artificial intelligence ecosystem. The FDA is moving quickly to ensure the development of a safe and effective artificial intelligence ecosystem in healthcare by releasing new documents intended to offer guidance to the health IT community. The agency has published a new Software Precertification (Pre-Cert) Pilot Program working model test plan and a regulatory framework explaining how it plans to regulate the next generation of digital health devices. The agency plans to exchange its traditional regulatory approaches for a model that offers more flexibility and faster, iterative review processes to accommodate the realities of the software development market and the fast-paced advancement of AI and machine learning. During 2019, the FDA will test the new model’s effectiveness through the Pre-Cert Pilot Program. “The goal of this phase of the pilot is to determine the contours of a possible regulatory model that provides efficient regulatory oversight of certain software-based medical devices from manufacturers who have demonstrated a robust culture of quality and organizational excellence (CQOE) and are committed to monitoring real-world performance while assuring that these devices are safe and effective,” the FDA explained. “In developing Version 1.0 of the program, the current focus is to establish processes for software as medical device (SaMD) technologies, which may include software functions that use artificial intelligence and machine learning algorithms.” The model would be implemented under the De Novo classification process, which is intended to create a speedy but thorough process for approving lower-risk medical devices. Full story - hTTps://
The following exemplifies and justifies Renalytix approach/entry into this underserved market, but it must surely serve as a serious reality check and wake-up call in the US! - December 7th, 2018 Posted by Kristina Sauerwein-Washington University The burden of chronic kidney disease, as well as the probability of death related to chronic kidney disease, have increased substantially over the past 15 years in all 50 US states, report researchers. Such increases also were seen in younger adults ages 20 to 54, a group in which kidney disease had been uncommon. The findings appear in JAMA Network Open. “It is particularly concerning that chronic kidney disease is becoming more common in younger people. This is a remarkable move in the wrong direction.” “The decline is largely reflective of medical advances in cardiovascular disease and cancer treatment,” Al-Aly says. “Similarly, the increase in chronic kidney disease reflects a relative stagnation in new treatments. There have been no major advances to slow or reverse kidney disease during the past two decades.” “Public health priorities, policy initiatives, funding allocation, and advocacy efforts need to catch up to this reality that the burden of chronic kidney disease is rising, and the speed of change now outpaces other noncommunicable diseases,” Al-Aly says. “A concerted effort should be made to put the brakes on this.” Full article (including link to study) - hTTps://
Thanks Charlie, I do now recall someone else saying the same just after the listing.
For info I bought through aj bell
9degrees...I assume that is indeed the case with regard to Barclays, but the shares are obviously available elsewhere. However, I am not sure if such sources would accommodate PI's.
How can Chris mills buy shares when Barclays smart investor says not available ? Is this share not available to Pi's until 22 april ?
I thought Renalytix would exercise that option, and strong IP is obviously a very important aspect, especially for small companies! I expect large pharma to be very interested in this fast evolving area of AI in kidney disease, where determining specific immunosuppression therapy levels is also being targeted and developed.
I note the share prices has been a bit erratic recently, which I thought the arrangements were meant to avoid! Anyway, I also note that Chris Mills has been taking advantage and added more shares to his already significant holding.
Interesting. Ta
Looks like Renalytix is ahead of the game with their Mount Sinai Health System partnership, not to mention proprietary prognostic biomarkers, which would appear to be a differentiating factor. That aside, the US appears to be seriously addressing and delivering what is needed (as other governments are) to accommodate not just the potential of AI in healthcare, but delivery from AI in healthcare! December 05, 2018 - Rucker: Without APIs, Artificial Intelligence Will Fail in Healthcare The success of artificial intelligence in healthcare depends on the widespread adoption of open APIs, says National Coordinator Dr. Don Rucker. As the healthcare industry looks just over the horizon to a busy, eventful, and competitive 2019, artificial intelligence tools are likely to take on an increasingly important role across the care continuum. Payers, providers, and health IT developers are pinning many of their hopes for lower costs and better outcomes on AI’s ability to recognize subtle patterns in huge volumes of data, streamline workflows, or suggest actions likely to produce better future results. For the Office of the National Coordinator (ONC), which is responsible for encouraging health IT adoption and fostering meaningful interoperability, artificial intelligence is both promising and potentially problematic. Machine learning certainly offers unparalleled possibilities to turn the industry’s big data assets into actionable insights, says National Coordinator Don Rucker, MD, and the ONC is confident that AI will play a major part in improving the delivery of care. But stakeholders may find it challenging to rapidly develop the technical foundations required to support AI, particularly the open application programming interfaces (APIs) that will allow organizations to feed data-hungry algorithms in a secure and standardized manner. However, that doesn’t mean that APIs should create a sudden data free-for-all, he added. “I want to be clear that APIs aren’t just an open door to do whatever you want with data,” Rucker stressed. “Anyone exchanging protected health data through an API is still bound by HIPAA, and they still have to seek appropriate consents from individuals to use their data for analytics or research.” Privacy and security are not the only challenges facing artificial intelligence developers who want to take advantage of APIs. Currently, healthcare-specific APIs only allow applications to draw on data at the individual level, Rucker explained. At some point during 2019, the group expects to be able to offer the industry the ability to transfer larger volumes of health data through the FHIR protocols. “These population-level queries are designed to use generally the same data structures and approaches as the individual queries we can complete, but scaled up to industrial strength,” said Rucker. “That's a critical building block for AI.” Once the capability is sufficiently developed and turned loose in the healthcare environment, Rucker believes that uptake will be swift and decisive, ushering in a new generation of AI opportunities. “I believe that within the next two years, we’re going to be using that ability broadly throughout the healthcare industry, and it is going to be revolutionary in many ways,” he predicted. “We have to be able to do this quickly. If we can't find a way to use APIs to their full capacity, then AI is simply not going to be operationalized in healthcare.” Full story - hTTps://
It’s great to see an innovative new venture join AIM. In the AIM sell-off, the shares have found little support in the short term and currently languish 15% below the admission price.
Here is the chance to meet with Renalytix: Using this unique discount code, ADVFN25, you will be able to get £25 off at Mello London 2018, a 2 day investor conference from the 26th – 27th November 2018 at the Clayton Hotel, Chiswick, London. Http:// Tickets are normally priced at £99 for two days and £79 for one. Type in ADVFN25 as the discount code. Many Thanks and take advantage of this premium offer.
The recent listings of Sensyne (SENS) (formerly known as Drayson Health) and Renalytix (RENX) have focused attention of UK investors on the new AI MedTech sector. Companies such as this in the AI/Machine Learning MedTech space "use anonymised data from the NHS to diagnose patterns in cancer and other diseases ...then pass on findings to drug companies so they can develop treatments faster and more cost-effectively than in the past." The rich valuations enjoyed by SENS and RENX have caused investors to look for other companies in the sector which may be 'hidden gems'. One such is Physiomics (PYC). Whilst Sensyne and Renalytix are valued at £240m and £70m despite have zero in revenues Physiomics is valued at only £3m AND has revenues of c. £0.5m However when considering how to value Physiomics it's important to realise there are two major strands to it's business. One strand is its 'legacy' Modelling and Simulation business which last year signed a E0.5m deal with Merck KgGA. This part of the business is analagous to the likes of Simulations Plus a $400m Mkt Cap Nasdaq listed comparitor with c.$20m in revenues. Thus one could apply a 'rating' of 10-20x revenues to value Physiomics business in this area. (£0.4m x 10-20x = £4.0-8.0m) The new strand to Physiomics business is it's AI/Personalised Medicine business. In this part of the business Physiomics has won research grant funding from the UK Government's InnovateUK to progress several studies on specific cancers in association with Oxford University academics and Oxford NHS. e.g. Oesophagal Cancer study hTtps:// Prostate Cancer study hTtps:// This part of Physiomics business is similar to and should be valued with reference to its newly listed comparitors Renalytix (RENX) and Sensyne (SENS). Those valuations would suggest a very wide potential range from £70m to £240m. Putting together the 'sum of the parts' we can conclude that a case can be made for valuing Physiomics currently as 'worth' somewhere within a range of £74-248m. In terms of share price with 72m shares in issue this would imply a potential valuation range of c.100-350p Clearly at a mere 5p the market has a lot of catching up to do in valuing Physiomics correctly.
the stigologist
PYC (4p ; Mkt Cap £3m) The case for a moonshoot spike to 100p is now inescapable after recent listing of AI biomedtech comparitors SENS and RENX SENS (Sensyne) Mkt Cap £240m Rev : £0m RENX (Renalytix) Mkt Cap £70m Rev : £0m PYC (Physiomics) Mkt Cap £3m Rev : £0.5m hTtps://
the stigologist
In the absence of ADVFN posting RNS announcements; I note that Lombard Odier A M bought 5.82% on the 6th. CD
Chat Pages: 2  1
Your Recent History
Renalytix ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190325 17:43:57